Protocol Ledger

NCT06612268 · Phase III · RECRUITING

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Interventional Phase III clinical trial protocol NCT06612268 sponsored by Novo Nordisk in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-17 Enrollment: 510 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06612268
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)510 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06612268
Protocol FieldVerified Registry Value
NCT IdentifierNCT06612268
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment510 participants (ESTIMATED)
Registered Start Date2025-02-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI